AZR
Azora Therapeutics
AZR | NASDAQ
$3.81
-$0.28 (-6.85%)
At close: Nov 16, 2026, 4:00 PM ET
Azora Therapeutics Company Profile
Company profile explainedCompany Profile
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Key Executives
| Name | Position |
|---|---|
| Julie Saiki | Co-Founder, Treasurer, Secretary & Director |
Azora Therapeutics
AZR
| Country | United States |
| IPO Date | Jul 27, 2018 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Cary J. Claiborne |
Contact Details
4267 Valley Meadow Road Encino,
California 91436 United States
Stock Details
| Ticker Symbol | AZR |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 054800107 |
| ISIN Number | US0548001074 |
| SIC Code | n/a |
Recent News
- 4 days ago / globenewswire.comAzora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
- 12 days ago / globenewswire.comAzora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Add to Watchlist
Select watchlists to add or remove AZR